CCN family member 3 Antibodies

CCN family member 3 (CCN3)

Immediate-early protein plays a role in various cellular processes such as proliferation, adhesion, migration, differentiation and survival (PubMed:15181016, PubMed:15611078, PubMed:12695522, PubMed:21344378, PubMed:12050162). Acts by binding to integrins or membrane receptors like NOTCH1 (PubMed:12695522, PubMed:21344378, PubMed:15611078).

Essential regulator of hematopoietic stem and progenitor cell function (PubMed:17463287). Inhibits vascular smooth muscle cells proliferation by increasing expression of cell-cycle regulators like CDKN2B or CDKN1A independently of TGFB1 signaling (PubMed:20139355).

Gene Information

Human
Gene Name:	CCN3
Uniprot:	P48745
Entrez:	4856

Family

Belongs to:
CCN family

Alternative Names

CCN family member 3

Molecular Weight

Mass (kDA):
39.162 kDA

Genomic Context

Human
Location:	8q24.12
Sequence:	8; NC_000008.11 (119416446..119424434)

Tissue Specificity

Expressed in endiothelial cells (at protein level) (PubMed:21063504). Expressed in bone marrow, thymic cells and nephroblastoma. Increased expression in Wilms tumor of the stromal type.

Subcellular Localizations

Secreted. Cytoplasm. Cell junction, gap junction. Localizes at the gap junction in presence of GJA1.

PTMs

• Disulfide bond
• Glycoprotein

• Lipoprotein
• Palmitate

For details, visit:
bosterbio.com/bosterbio-gene-info-cards/CCN3

Best Uses Of The CCN3 Marker From Boster Bio

Boster Bio provides information on the benefits of high-affinity primary antibody. This guide will assist you in optimizing your experiments. Optimizing flow procedures can prove difficult. This guide will give you tips to improve your experiments and answer your questions. Boster Bio's CCN3 Marker is a versatile marker that is very popular. It is used to determine gene expression levels within the body.

Boster Bio optimization tips

Boster Bio supplies the standard CCN3 antibody as well as isotype and IHC detection systems. The company is available to answer customer questions and address most concerns regarding negative control conditions. Here are three tips for ensuring accurate and reliable CCN3 results:

History of Steven Boster

If you are searching for information on Steven Boster, you have come to the right place. This biography provides the background information about this man. Steven Boster, a man well-known for his natural ability to make science a passion, founded the company in 1993. His early work consisted of the development of hundreds if not thousands of primary antibody and various products in immunohistochemistry (IHC). By the late nineties, he had become the largest catalog antibody company in China. His success in the biotechnology sector led to the invention of PicoKine(tm), a proprietary ELISA platform. PicoKine (tm) is a patent technology that produces high-sensitivity ELISA kit kits.

Steven Boster's story was filled with colorful family members. He was the child of Evelyn Meier (and James Boster). He was an outstanding manager of retail sales for many years. He was a Concordia Hall graduate and served in the U.S. Army. Steve is survived also by his wife, Natosha Peck and Crystal Boster. There are six grandchildren and four brother Jack Boster. Many nieces and nephews also survive him.

Primary antibodies with high affinity

High-affinity primary antibodies against this protein were created by molecular copying of the human CCN3 gene. These antibodies can detect full-length CCN3 as well as truncated proteins. They also detect CCN3's structural structure. This method allows high-affinity primary antibodies to CCN3 to be used for screening human tumors for expression of CCN3 protein.

Previously, only antibodies recognizing haptens were tested. A variety of affinity maturation stages were represented by antibodies that recognize antigens. An increase in affinity was associated with the number somatic mutations. Improved affinity was not due formation of additional salt bridges or hydrogen bonds but to the burial of the hydrophobic material. This process resulted in antibodies that could bind to VHEL peptide 3000 times more tightly.

Aims of affinity maturation include the rebuilding of antibody clonal linesages. NGS has made this possible by allowing reconstruction of the antibody clonal lineages and inferring the germ line progenitor sequences. These sequences could not be the true ancestor sequences. However, mutations in the VL and VH gene segments can be easily identified. The original VLJL-VHDJH junctional sequencing are not known. Affinity maturation cannot determine whether there were any insertions, deletions, or both.

CCN3 proteins are one of three founder proteins within the CCN family. CCN3 expression is low in the human body's arterial smooth muscle cells, podocytes, and medullaryinterstitium. CCN3 expression peaks 2 days after cell proliferation. CCN3 expression has been linked to a wide range of cancers, fibrotic diseases, and other conditions.

CCN3 immunoreactivity could also be assessed using NH antibodies, which recognize the cellular expression. CCN3 proteins have been found in osteosarcoma cell lines and choriocarcinoma. These antibodies have similar immunoreactivity to polyclonal antibody. High-affinity primary antibody against CCN3 is a promising tool for immunotherapy research in cancer.

Subset of genes that are CCN3 Markers

Gene applicants have successfully identified CCN3 as a new biomarker for many diseases, including diabetes and ovarian cancer. These genes encode a specific protein structure that is recognized as a gene's antigen. Gene applicants have also identified signaling molecule expression by different immune cell types, which is in addition to identifying genes of particular interest. These molecules are expressed in a variety of immune cell types, including the salivary and trachea.